Monte Rosa Therapeutics, Inc. SEC filings GLUE
Monte Rosa Therapeutics, Inc. has 401 filings in SEC EDGAR's recent list, going back to Sep 29, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 17, 2026 | Mar 17, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 10, 2026 | Feb 9, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jan 9, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Other events
|
Jan 7, 2026 | Jan 7, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 7, 2026 | Jan 7, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 16, 2025 | Dec 16, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 15, 2025 | Sep 15, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 13, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 8, 2025 | May 8, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 20, 2025 | Mar 20, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 10, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 13, 2024 | Dec 11, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 5, 2024 | Dec 5, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 28, 2024 | Oct 25, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 27, 2024 | Jun 27, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2024 | Jun 12, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 30, 2024 | May 28, 2024 |
| 8-K |
Current report
Material agreement
|
May 16, 2024 | May 15, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 2, 2024 | Apr 29, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 14, 2024 | Mar 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 26, 2023 | Oct 26, 2023 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Oct 17, 2023 | Oct 16, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Jul 26, 2023 | Jul 26, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 14, 2023 | Jun 14, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 23, 2023 | Mar 22, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 16, 2023 | Mar 16, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 24, 2022 | Oct 24, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2022 | Jun 15, 2022 |
| 8-K |
Current report
Results of operations
|
May 11, 2022 | May 11, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2022 | Mar 29, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Dec 15, 2021 | Dec 14, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 28, 2021 | Jun 28, 2021 |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- GLUE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1826457
- Former names
- Monte Rosa Therapeutics, Inc. (until Nov 5, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.